Shots:

• Moleculin will provide its lead candidate- WP1122- and related inhibitors along with technical support while UTMB will investigate candidates against multiple viruses including COVID-19- in connection with UTMB’s CBEID
• UTMB’s CBEID collaborates with the Galveston National Laboratory- which is funded by NIAID the US Department of Defense- the US Centers for Disease Control & Prevention and other federal agencies along with academic partners- private foundations- and the biopharmaceutical industry
• WP1122 is a prodrug of 2-DG (2-deoxy-D-glucose) that overcome 2-DG's lack of drug-like properties and demonstrated increment in the tissue/organ concentration in its preclinical study

Click here ­to­ read full press release/ article | Ref: Moleculin | Image: Moleculin